AMGN vs REGN Comparison: AI Score, Valuation, Performance and Upside
Compare Amgen and Regeneron by biosimilar exposure, GLP-1 obesity drug pipeline (MariTide), Dupixent vs Enbrel replacement, free cash flow, and which established biotech offers better risk-adjusted long-term returns.
Use this Amgen vs Regeneron comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
REGN holds the edge across 3 of 5 key metrics in this comparison. REGN leads on both 1-year return (+35.85%) and forward P/E quality (12.78x vs 16.43x for AMGN), a relatively favorable combination of momentum and valuation. On fundamentals, REGN is growing revenue faster (16.70%), while AMGN maintains the higher operating margin (33.80%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for REGN (+9.30%) than for AMGN (-7.30%).
| Metric | AMGN | REGN |
|---|---|---|
| AI score | 48.0 | 42.8 |
| AI rank | #570 | #827 |
| Latest close | $378.87 | $759.24 |
| 1M return | +1.26% | +16.04% |
| 6M return | +9.92% | +0.56% |
| 1Y return | +27.62% | +35.85% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | AMGN | REGN |
|---|---|---|
| 1Y ago | $12.55K (+25.5%) started 2025-08-04 | $13.28K (+32.8%) started 2025-08-04 |
| 5Y ago | $21.08K (+110.8%) started 2021-08-05 | $12.65K (+26.5%) started 2021-08-05 |
| 10Y ago | $38.76K (+287.6%) started 2016-08-05 | $18.02K (+80.2%) started 2016-08-05 |
Hypothetical — past performance does not guarantee future results.
| Metric | AMGN | REGN |
|---|---|---|
| Market cap | $207.87B | $78.52B |
| Trailing P/E | 26.80 | 18.87 |
| Forward P/E | 16.43 | 12.78 |
| Price/Sales | 4.57 | 3.78 |
| EV/Revenue | 6.80 | 4.56 |
| Analyst target | $357.03 | $833.54 |
| Target upside | -7.30% | +9.30% |
| Metric | AMGN | REGN |
|---|---|---|
| Revenue growth | 5.80% | 16.70% |
| Earnings growth | 4.40% | -4.50% |
| EPS growth | +4.40% | -4.50% |
| FCF margin | +19.98% | +19.73% |
| Operating margin | 33.80% | 33.11% |
| Profit margin | 20.96% | 27.87% |
| ROIC proxy | 101.32% | 14.04% |
| Return on equity | 101.32% | 14.04% |
| Dividend yield | 2.62% | 0.49% |
| Beta | 0.40 | 0.24 |
| Debt/equity | 623.75 | 8.54 |
| Current ratio | 1.26 | 3.33 |
| Quick ratio | 0.85 | 2.63 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | AMGN | REGN |
|---|---|---|---|
| 1Y | Growth | +25.48% | +32.84% |
| CAGR | +25.55% | +32.93% | |
| Sharpe ratio | 0.81 | 0.88 | |
| Max drawdown | 16.57% | 26.05% | |
| Max daily drop | 5.14% | 9.82% | |
| Max wkly drop | 8.70% | 12.87% | |
| 5Y | Growth | +84.00% | +26.37% |
| CAGR | +12.98% | +4.80% | |
| Sharpe ratio | 0.44 | 0.16 | |
| Max drawdown | 24.86% | 59.69% | |
| Max daily drop | 7.14% | 19.01% | |
| Max wkly drop | 12.81% | 20.21% | |
| 10Y | Growth | +185.38% | +79.99% |
| CAGR | +11.06% | +6.06% | |
| Sharpe ratio | 0.37 | 0.20 | |
| Max drawdown | 24.86% | 59.69% | |
| Max daily drop | 9.58% | 19.01% | |
| Max wkly drop | 15.79% | 20.21% |
| Category | AMGN | REGN |
|---|---|---|
| Company | AMGN | REGN |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Biotechnology |
| Core business | N/A | N/A |
| Investor focus | N/A | N/A |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.